Lexicon (LXRX) Pharmaceuticals announced the completion of patient enrollment in the PROGRESS study evaluating LX9211, a novel, orally-delivered, selective investigational small molecule inhibitor of adaptor-associated kinase 1, for the treatment of diabetic peripheral neuropathic pain, DPNP. The study successfully enrolled 494 patients, approximately 20 percent more than originally targeted, marking a significant milestone in the trial and increasing study power. Top-line data from PROGRESS is expected to be announced in Q1 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon price target lowered to $4 from $6 at H.C. Wainwright
- Lexicon to eliminate commercial organization, focus on clinical development
- Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
- Lexicon announces data from four stories of sotagliflozin to be delivered
- Lexicon Pharmaceuticals Reports Q3 2024 Financial Results